Direct Oral Anticoagulants in the Setting of Percutaneous Coronary Intervention: “There Will Be Blood”

Direct oral anticoagulants (DOACs) are being increasingly used in clinical practice for various indications ranging from treatment of venous thromboembolism1 to stroke thromboprophylaxis in atrial fibrillation.2 Clinical practice guidelines now endorse DOACs in preference to vitamin K antagonists (VKAs) for thromboprophylaxis in patients with atrial fibrillation and after venous thromboembolism, reflecting the favorable efficacy and safety profile of this anticoagulant class compared with VKA.3 Despite increasing DOAC utilization, the optimal periprocedural antithrombotic management for patients treated with DOAC who underwent percutaneous coronary intervention (PCI) has not been established.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research